NASDAQ:CSBR

Champions Oncology Competitors

$10.86
-0.44 (-3.89 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.66
Now: $10.86
$11.53
50-Day Range
$10.72
MA: $11.69
$13.75
52-Week Range
$7.05
Now: $10.86
$14.68
Volume22,115 shs
Average Volume30,982 shs
Market Capitalization$145.42 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2

Competitors

Champions Oncology (NASDAQ:CSBR) Vs. PSTX, OYST, SLDB, DTIL, AVRO, and GRTS

Should you be buying CSBR stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Champions Oncology, including Poseida Therapeutics (PSTX), Oyster Point Pharma (OYST), Solid Biosciences (SLDB), Precision BioSciences (DTIL), AVROBIO (AVRO), and Gritstone Oncology (GRTS).

Champions Oncology (NASDAQ:CSBR) and Poseida Therapeutics (NASDAQ:PSTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings and analyst recommendations.

Insider & Institutional Ownership

52.8% of Champions Oncology shares are owned by institutional investors. Comparatively, 41.1% of Poseida Therapeutics shares are owned by institutional investors. 46.8% of Champions Oncology shares are owned by company insiders. Comparatively, 19.0% of Poseida Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for Champions Oncology and Poseida Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Champions Oncology00103.00
Poseida Therapeutics00303.00

Champions Oncology currently has a consensus target price of $16.00, indicating a potential upside of 47.33%. Poseida Therapeutics has a consensus target price of $25.00, indicating a potential upside of 171.74%. Given Poseida Therapeutics' higher possible upside, analysts plainly believe Poseida Therapeutics is more favorable than Champions Oncology.

Valuation and Earnings

This table compares Champions Oncology and Poseida Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Champions Oncology$32.12 million4.53$-1,980,000.00($0.17)-63.88
Poseida TherapeuticsN/AN/AN/A($6.86)-1.34

Poseida Therapeutics has lower revenue, but higher earnings than Champions Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than Poseida Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Champions Oncology and Poseida Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Champions Oncology-4.18%-29.93%-7.41%
Poseida TherapeuticsN/AN/AN/A

Summary

Poseida Therapeutics beats Champions Oncology on 6 of the 10 factors compared between the two stocks.

Champions Oncology (NASDAQ:CSBR) and Oyster Point Pharma (NASDAQ:OYST) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Institutional & Insider Ownership

52.8% of Champions Oncology shares are held by institutional investors. Comparatively, 70.2% of Oyster Point Pharma shares are held by institutional investors. 46.8% of Champions Oncology shares are held by insiders. Comparatively, 36.9% of Oyster Point Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Champions Oncology and Oyster Point Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Champions Oncology00103.00
Oyster Point Pharma00103.00

Champions Oncology presently has a consensus target price of $16.00, suggesting a potential upside of 47.33%. Given Champions Oncology's higher probable upside, research analysts plainly believe Champions Oncology is more favorable than Oyster Point Pharma.

Earnings and Valuation

This table compares Champions Oncology and Oyster Point Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Champions Oncology$32.12 million4.53$-1,980,000.00($0.17)-63.88
Oyster Point PharmaN/AN/A$-45,710,000.00($9.97)-2.09

Champions Oncology has higher revenue and earnings than Oyster Point Pharma. Champions Oncology is trading at a lower price-to-earnings ratio than Oyster Point Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Champions Oncology and Oyster Point Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Champions Oncology-4.18%-29.93%-7.41%
Oyster Point PharmaN/A-39.61%-37.68%

Volatility & Risk

Champions Oncology has a beta of 1.2, meaning that its share price is 20% more volatile than the S&P 500. Comparatively, Oyster Point Pharma has a beta of -0.38, meaning that its share price is 138% less volatile than the S&P 500.

Summary

Champions Oncology beats Oyster Point Pharma on 8 of the 11 factors compared between the two stocks.

Solid Biosciences (NASDAQ:SLDB) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Solid Biosciences and Champions Oncology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Solid Biosciences01402.80
Champions Oncology00103.00

Solid Biosciences currently has a consensus target price of $12.40, suggesting a potential upside of 153.06%. Champions Oncology has a consensus target price of $16.00, suggesting a potential upside of 47.33%. Given Solid Biosciences' higher probable upside, equities analysts clearly believe Solid Biosciences is more favorable than Champions Oncology.

Insider & Institutional Ownership

42.7% of Solid Biosciences shares are held by institutional investors. Comparatively, 52.8% of Champions Oncology shares are held by institutional investors. 31.2% of Solid Biosciences shares are held by company insiders. Comparatively, 46.8% of Champions Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Solid Biosciences and Champions Oncology's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solid BiosciencesN/AN/A$-117,220,000.00($2.91)-1.68
Champions Oncology$32.12 million4.53$-1,980,000.00($0.17)-63.88

Champions Oncology has higher revenue and earnings than Solid Biosciences. Champions Oncology is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Solid Biosciences has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

Profitability

This table compares Solid Biosciences and Champions Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Solid BiosciencesN/A-194.22%-140.40%
Champions Oncology-4.18%-29.93%-7.41%

Summary

Champions Oncology beats Solid Biosciences on 9 of the 13 factors compared between the two stocks.

Precision BioSciences (NASDAQ:DTIL) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, earnings, analyst recommendations and profitability.

Earnings and Valuation

This table compares Precision BioSciences and Champions Oncology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Precision BioSciences$22.24 million23.43$-92,880,000.00($1.91)-4.77
Champions Oncology$32.12 million4.53$-1,980,000.00($0.17)-63.88

Champions Oncology has higher revenue and earnings than Precision BioSciences. Champions Oncology is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Precision BioSciences and Champions Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Precision BioSciences01402.80
Champions Oncology00103.00

Precision BioSciences presently has a consensus target price of $20.00, suggesting a potential upside of 119.30%. Champions Oncology has a consensus target price of $16.00, suggesting a potential upside of 47.33%. Given Precision BioSciences' higher probable upside, equities analysts clearly believe Precision BioSciences is more favorable than Champions Oncology.

Insider & Institutional Ownership

48.6% of Precision BioSciences shares are owned by institutional investors. Comparatively, 52.8% of Champions Oncology shares are owned by institutional investors. 14.3% of Precision BioSciences shares are owned by insiders. Comparatively, 46.8% of Champions Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Precision BioSciences and Champions Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Precision BioSciences-484.81%-105.74%-53.08%
Champions Oncology-4.18%-29.93%-7.41%

Volatility & Risk

Precision BioSciences has a beta of 2.08, suggesting that its stock price is 108% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.

Summary

Champions Oncology beats Precision BioSciences on 9 of the 14 factors compared between the two stocks.

AVROBIO (NASDAQ:AVRO) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current ratings and recommmendations for AVROBIO and Champions Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AVROBIO03502.63
Champions Oncology00103.00

AVROBIO currently has a consensus target price of $26.00, suggesting a potential upside of 129.48%. Champions Oncology has a consensus target price of $16.00, suggesting a potential upside of 47.33%. Given AVROBIO's higher possible upside, equities analysts clearly believe AVROBIO is more favorable than Champions Oncology.

Earnings and Valuation

This table compares AVROBIO and Champions Oncology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AVROBION/AN/A$-72,960,000.00($2.66)-4.26
Champions Oncology$32.12 million4.53$-1,980,000.00($0.17)-63.88

Champions Oncology has higher revenue and earnings than AVROBIO. Champions Oncology is trading at a lower price-to-earnings ratio than AVROBIO, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

AVROBIO has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.

Institutional & Insider Ownership

86.7% of AVROBIO shares are held by institutional investors. Comparatively, 52.8% of Champions Oncology shares are held by institutional investors. 4.8% of AVROBIO shares are held by company insiders. Comparatively, 46.8% of Champions Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares AVROBIO and Champions Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AVROBION/A-51.33%-47.65%
Champions Oncology-4.18%-29.93%-7.41%

Summary

Champions Oncology beats AVROBIO on 7 of the 13 factors compared between the two stocks.

Gritstone Oncology (NASDAQ:GRTS) and Champions Oncology (NASDAQ:CSBR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Gritstone Oncology and Champions Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gritstone Oncology-2,962.52%-101.31%-68.78%
Champions Oncology-4.18%-29.93%-7.41%

Earnings & Valuation

This table compares Gritstone Oncology and Champions Oncology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gritstone Oncology$4.36 million104.53$-94,430,000.00($2.81)-3.31
Champions Oncology$32.12 million4.53$-1,980,000.00($0.17)-63.88

Champions Oncology has higher revenue and earnings than Gritstone Oncology. Champions Oncology is trading at a lower price-to-earnings ratio than Gritstone Oncology, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

59.0% of Gritstone Oncology shares are held by institutional investors. Comparatively, 52.8% of Champions Oncology shares are held by institutional investors. 38.0% of Gritstone Oncology shares are held by company insiders. Comparatively, 46.8% of Champions Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Gritstone Oncology and Champions Oncology, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gritstone Oncology10202.33
Champions Oncology00103.00

Gritstone Oncology currently has a consensus price target of $22.3333, suggesting a potential upside of 139.89%. Champions Oncology has a consensus price target of $16.00, suggesting a potential upside of 47.33%. Given Gritstone Oncology's higher possible upside, equities analysts plainly believe Gritstone Oncology is more favorable than Champions Oncology.

Volatility & Risk

Gritstone Oncology has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Champions Oncology has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

Summary

Champions Oncology beats Gritstone Oncology on 8 of the 13 factors compared between the two stocks.


Champions Oncology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$9.20-3.3%$571.39 millionN/A-1.34News Coverage
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$20.83-4.5%$539.71 millionN/A-6.00Analyst Upgrade
News Coverage
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$4.90-1.4%$523.70 millionN/A-2.38
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$9.12-0.4%$521.14 million$22.24 million-4.54
AVROBIO logo
AVRO
AVROBIO
1.7$11.33-2.1%$471.58 millionN/A-3.43
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$9.31-0.3%$455.74 million$4.36 million-3.26Analyst Upgrade
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.04-3.6%$447.75 millionN/A-7.88
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.6$11.90-0.8%$426.67 millionN/A0.00Gap Down
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$9.06-2.6%$411.27 million$147.87 million-3.01
Opthea logo
OPT
Opthea
1.5$8.91-0.6%$387.20 millionN/A0.00
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$2.17-4.6%$376.73 million$8.15 million-1.74
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$8.68-0.7%$363.22 millionN/A0.00
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$12.69-0.0%$353.67 millionN/A0.00Lockup Expiration
Codiak BioSciences logo
CDAK
Codiak BioSciences
2.0$15.78-25.7%$347.07 millionN/A0.00High Trading Volume
News Coverage
Gap Down
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$8.80-4.0%$330.46 million$250,000.00-3.14Analyst Upgrade
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.09-1.5%$323.07 million$96.12 million-12.03
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.3$5.59-1.1%$292.61 million$2.91 million-1.95
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.8$8.49-1.5%$287.82 millionN/A-3.49News Coverage
Surface Oncology logo
SURF
Surface Oncology
1.4$6.63-2.6%$276.66 million$15.36 million-10.05
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$11.32-1.6%$272.39 millionN/A-8.26High Trading Volume
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.90-8.4%$230.42 million$29.35 million-2.21High Trading Volume
Gap Down
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.64-3.0%$229.27 million$4.13 million-3.64
Genfit logo
GNFT
Genfit
1.3$4.33-0.2%$193.05 million$45.88 million-2.20News Coverage
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$5.88-1.2%$188.31 millionN/A-3.67
Gamida Cell logo
GMDA
Gamida Cell
1.4$7.70-1.8%$186.49 millionN/A-5.38
INmune Bio logo
INMB
INmune Bio
1.5$12.39-5.2%$185.02 millionN/A-12.77Analyst Report
Gap Up
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.88-0.4%$178.90 millionN/A-8.39Analyst Report
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$4.70-1.9%$176.97 million$104.39 million-2.87
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$4.10-0.2%$175.28 million$2.45 million-1.92
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$14.94-0.0%$167.76 millionN/A0.00
Axcella Health logo
AXLA
Axcella Health
1.6$4.28-0.0%$161.31 millionN/A-1.99News Coverage
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$9.13-1.5%$158.72 millionN/A-2.85News Coverage
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$7.21-0.6%$155.92 millionN/A-1.84
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$6.74-4.9%$145.71 millionN/A0.00Gap Down
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$4.41-1.8%$139.97 million$20,000.000.00Analyst Upgrade
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.4$10.41-1.0%$137.10 million$2.33 million0.00
Dyadic International logo
DYAI
Dyadic International
1.3$4.85-0.6%$133.64 million$1.68 million-14.26
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.43-7.0%$130.05 millionN/A-1.68Upcoming Earnings
News Coverage
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.4$12.47-1.5%$127.52 millionN/A0.00
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.30-0.6%$117.88 millionN/A-3.14Upcoming Earnings
TRACON Pharmaceuticals logo
TCON
TRACON Pharmaceuticals
1.7$7.55-2.8%$116.87 million$3 million-2.43Analyst Upgrade
News Coverage
PolarityTE logo
PTE
PolarityTE
1.4$0.95-5.3%$114.85 million$5.65 million-0.57Gap Down
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$4.18-1.2%$114.65 million$23.05 million-1.86
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.18-0.5%$104.73 million$20.92 million-1.25
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$2.12-0.0%$101.38 million$140,000.000.00
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.17-2.6%$66.62 millionN/A-0.93
Organovo logo
ONVO
Organovo
0.7$9.15-1.2%$65.12 million$2.20 million0.00
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$4.02-5.2%$64.36 million$420,000.00-1.51
Kiromic BioPharma logo
KRBP
Kiromic BioPharma
1.0$8.50-1.6%$62.33 millionN/A0.00Gap Down
BioCardia logo
BCDA
BioCardia
1.3$3.68-0.0%$60.13 million$710,000.00-1.90Analyst Report
This page was last updated on 4/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.